TIFFANY GRAMBLIN: Open Payments
NPI 1760849343 · ACKLEY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$474 in 25 payments from 13 companies in 2025. Trend: 2023 $285 · 2024 $339 · 2025 $474
Food & beverage: $450Speaker / faculty: $24
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
| Lilly USA, LLC | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Becton, Dickinson and Company | 1 | $24 |
| Amgen Inc. | 1 | $21 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| Novo Nordisk Inc | 1 | $17 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $16 |
Products named: REXULTI, VRAYLAR, MOUNJARO, AIRSUPRA, CAPLYTA, Power-Trialysis, EVENITY, CAPVAXIVE.
Industry payments across IA — which companies pay providers there.
